BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, Golani LK, Cook JM, Witkin JM. GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA(A) receptors. Pharmacol Ther 2022;234:108035. [PMID: 34793859 DOI: 10.1016/j.pharmthera.2021.108035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Singewald N, Sartori SB, Reif A, Holmes A. Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology 2023;226:109418. [PMID: 36623804 DOI: 10.1016/j.neuropharm.2023.109418] [Reference Citation Analysis]
2 Ping X, Meyer MJ, Zahn NM, Golani LK, Sharmin D, Pandey KP, Revanian S, Mondal P, Jin X, Arnold LA, Cerne R, Cook JM, Divović B, Savić MM, Lippa A, Smith JL, Witkin JM. Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog. Drug Dev Res 2023. [PMID: 36748904 DOI: 10.1002/ddr.22042] [Reference Citation Analysis]
3 Keam SJ, Al-salama ZT. Ganaxolone in seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: a profile of its use in the USA. Drugs Ther Perspect 2023. [DOI: 10.1007/s40267-022-00976-w] [Reference Citation Analysis]
4 Marileo AM, Gavilán J, San Martín VP, Lara CO, Sazo A, Muñoz-Montesino C, Castro PA, Burgos CF, Leiva-Salcedo E, Aguayo LG, Moraga-Cid G, Fuentealba J, Yévenes GE. Modulation of GABA(A) receptors and of GABAergic synapses by the natural alkaloid gelsemine. Front Mol Neurosci 2022;15:1083189. [PMID: 36733271 DOI: 10.3389/fnmol.2022.1083189] [Reference Citation Analysis]
5 Zhang M, Kou L, Qin Y, Chen J, Bai D, Zhao L, Lin H, Jiang G. A bibliometric analysis of the recent advances in diazepam from 2012 to 2021. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1042594] [Reference Citation Analysis]
6 Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin Drug Discov 2022;17:1131-46. [PMID: 35934973 DOI: 10.1080/17460441.2022.2111415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Grötsch MK, Wietor DM, Hettich T, Ehlert U. Validation of a Commercial Enzyme-Linked Immunosorbent Assay for Allopregnanolone in the Saliva of Healthy Pregnant Women. Biomolecules 2022;12:1381. [DOI: 10.3390/biom12101381] [Reference Citation Analysis]
8 Fernandes H, Batalha V, Braksator E, Hebeisen S, Bonifácio MJ, Vieira-Coelho MA, Soares-da-Silva P. Voltage-clamp evidence of GABAA receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem. Pharmacol Rep 2022. [PMID: 36097257 DOI: 10.1007/s43440-022-00411-x] [Reference Citation Analysis]
9 Quagliato LA, Carta MG, Nardi AE. Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target? J Clin Psychopharmacol 2022;42:427-8. [PMID: 36099401 DOI: 10.1097/JCP.0000000000001591] [Reference Citation Analysis]
10 Mian MY, Divović B, Sharmin D, Pandey KP, Golani LK, Tiruveedhula VVNPB, Cerne R, Smith JL, Ping X, Jin X, Imler GH, Deschamps JR, Lippa A, Cook JM, Savić MM, Rowlett J, Witkin JM. Hydrochloride Salt of the GABAkine KRM-II-81. ACS Omega. [DOI: 10.1021/acsomega.2c03029] [Reference Citation Analysis]
11 Jarema KA, Hunter DL, Hill BN, Olin JK, Britton KN, Waalkes MR, Padilla S. Developmental Neurotoxicity and Behavioral Screening in Larval Zebrafish with a Comparison to Other Published Results. Toxics 2022;10:256. [DOI: 10.3390/toxics10050256] [Reference Citation Analysis]
12 Golani LK, Divović B, Sharmin D, Pandey KP, Mian MY, Cerne R, Zahn NM, Meyer MJ, Tiruveedhula VVNPB, Smith JL, Ping X, Jin X, Lippa A, Schkeryantz JM, Arnold LA, Cook JM, Savić MM, Witkin JM. Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3-selective GABAkine KRM-II-81. Biopharm Drug Dispos 2022;43:66-75. [PMID: 35194800 DOI: 10.1002/bdd.2313] [Reference Citation Analysis]
13 Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, Kivell BM, Knutson DE, Sharmin D, Pandey KP, Mian MY, Cook JM, Cerne R. The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacol Biochem Behav 2022;:173321. [PMID: 35041859 DOI: 10.1016/j.pbb.2021.173321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]